Roche: Tecentriq approved as treatment of liver cancer
(CercleFinance.com) - Roche has announced that the European Commission has approved Tecentriq, in combination with Avastin, for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have not received previous systemic therapy.
The approval is based on the results of the phase III study IMbrave150, published in the NEJM last May, which showed that this combination reduces the risk of death by 42% and the risk of the disease worsening or death by 41% compared to sorafenib.
Roche says that it has an extensive development program for Tecentriq, including ongoing and planned phase III studies in various types of lung, skin, breast, gastrointestinal and gynecological cancers.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
The approval is based on the results of the phase III study IMbrave150, published in the NEJM last May, which showed that this combination reduces the risk of death by 42% and the risk of the disease worsening or death by 41% compared to sorafenib.
Roche says that it has an extensive development program for Tecentriq, including ongoing and planned phase III studies in various types of lung, skin, breast, gastrointestinal and gynecological cancers.
Copyright (c) 2020 CercleFinance.com. All rights reserved.